Immunocore (NASDAQ:IMCR) Stock Price Crosses Above 200-Day Moving Average – Time to Sell?

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $31.83 and traded as high as $32.00. Immunocore shares last traded at $31.96, with a volume of 314,115 shares changing hands.

Analyst Ratings Changes

IMCR has been the topic of several analyst reports. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. TD Cowen raised shares of Immunocore to a “strong-buy” rating in a research report on Monday, August 24th. Zacks Research lowered shares of Immunocore from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 3rd. Finally, Morgan Stanley set a $43.00 price objective on shares of Immunocore in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.38.

Immunocore Price Performance

The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -84.51 and a beta of 0.81. The company has a current ratio of 4.47, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. The company’s 50 day moving average is $32.59 and its 200 day moving average is $31.83.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%. Research analysts anticipate that Immunocore Holdings PLC Sponsored ADR will post 0.04 EPS for the current fiscal year.

Institutional Trading of Immunocore

Several institutional investors and hedge funds have recently bought and sold shares of IMCR. Rockefeller Capital Management L.P. purchased a new position in Immunocore during the 4th quarter worth $47,000. GAMMA Investing LLC boosted its stake in shares of Immunocore by 202.8% during the second quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock worth $61,000 after buying an additional 1,286 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Immunocore during the third quarter worth $72,000. Juncture Wealth Strategies LLC acquired a new position in Immunocore during the 3rd quarter worth approximately $207,000. Finally, denkapparat Operations GmbH purchased a new position in shares of Immunocore during the 2nd quarter worth approximately $209,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.